Brokerages predict that AstraZeneca plc (NYSE:AZN) will announce earnings of $0.44 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for AstraZeneca’s earnings, with the lowest EPS estimate coming in at $0.38 and the highest estimate coming in at $0.53. AstraZeneca posted earnings per share of $1.21 in the same quarter last year, which would indicate a negative year-over-year growth rate of 63.6%. The company is expected to issue its next earnings results before the market opens on Friday, February 2nd.
According to Zacks, analysts expect that AstraZeneca will report full year earnings of $1.92 per share for the current financial year, with EPS estimates ranging from $1.87 to $2.02. For the next financial year, analysts anticipate that the company will report earnings of $1.72 per share, with EPS estimates ranging from $1.58 to $1.81. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover AstraZeneca.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The business’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.32 earnings per share.
AstraZeneca (NYSE AZN) traded up $0.48 during trading hours on Friday, hitting $36.63. The company had a trading volume of 5,029,106 shares, compared to its average volume of 3,180,000. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The company has a market capitalization of $91,400.00, a P/E ratio of 26.16, a PEG ratio of 2.67 and a beta of 0.76. AstraZeneca has a fifty-two week low of $26.51 and a fifty-two week high of $36.70.
A number of hedge funds and other institutional investors have recently modified their holdings of AZN. Advisor Partners LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $221,000. Hardman Johnston Global Advisors LLC bought a new position in shares of AstraZeneca during the fourth quarter worth approximately $35,125,000. Lourd Capital LLC bought a new position in shares of AstraZeneca during the fourth quarter worth approximately $791,000. Flagship Harbor Advisors LLC bought a new position in shares of AstraZeneca during the fourth quarter worth approximately $227,000. Finally, Fisher Asset Management LLC increased its stake in shares of AstraZeneca by 2.7% during the fourth quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock worth $413,531,000 after purchasing an additional 315,759 shares during the period. 14.76% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/28/analysts-expect-astrazeneca-plc-azn-will-announce-earnings-of-0-44-per-share.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.